Multi institutional retrospective study on clinicopathological significance of serum p53 antibody in the patients with esophageal cancer

Not Applicable

• Conditions: Esophageal cancer

• Registration Number: JPRN-UMIN000027994
• Lead Sponsor: Toho University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-07-01
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Not provided

Exclusion Criteria

-Active multiple primary cancer (Synchronous or metachronous primary cancer within 5 years without disease-free disease, except that carcinoma in situ or intratumoral carcinoma lesion judged to be cured by topical treatment is active multiple primary cancer not included in cancer)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-Tumor marker levels p53 antibody, CEA, SCC antigen, CYFRA 21-1 (CYFRA 21-1 is not essential) -Clinicopathological factors *UICC classification before surgery *Presence and detail of preoperative treatment and details (chemotherapy, radiation therapy) *Presence and detail of postoperative treatment and adjuvant chemotherapy (regimen, radiation therapy) *Recurrence site -Lavoratory data (CRP, T-cho, Alb, WBC)